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Abstract
Despite rapid progress in genomic profiling in acute lymphoblastic leukemia (ALL), identification of actionable targets
and prediction of response to drugs remains challenging. To identify specific vulnerabilities in ALL, we performed a
drug screen using primary human ALL samples cultured in a model of the bone marrow microenvironment
combined with high content image analysis. Among the 2487 FDA-approved compounds tested, anthelmintic
agents of the class of macrocyclic lactones exhibited potent anti-leukemia activity, similar to the already known anti-
leukemia agents currently used in induction chemotherapy. Ex vivo validation in 55 primary ALL samples of both
precursor B cell and T-ALL including refractory relapse cases confirmed strong anti-leukemia activity with IC50 values
in the low micromolar range. Anthelmintic agents increased intracellular chloride levels in primary leukemia cells,
inducing mitochondrial outer membrane depolarization and cell death. Supporting the notion that simultaneously
targeting cell death machineries at different angles may enhance the cell death response, combination of
anthelmintic agents with the BCL-2 antagonist navitoclax or with the chemotherapeutic agent dexamethasone
showed synergistic activity in primary ALL. These data reveal anti-leukemia activity of anthelmintic agents and
support exploiting drug repurposing strategies to identify so far unrecognized anti-cancer agents with potential to
eradicate even refractory leukemia.
Introduction
Intensive chemotherapy regimens in childhood lym-
phoblastic leukemia (ALL) have led to substantial
improvement in survival, which now overcomes 80%1,2.
Despite these advances, relapsed leukemia rank among
the most frequent diagnoses in childhood malignancies,
and remain a major clinical problem, being often asso-
ciated with fatal outcome3. While powerful new immu-
notherapeutic approaches are currently being developed
in particular in B cell precursor ALL (BCP-ALL)4–6,
identification of small molecules with anti-leukemic
potential that could be incorporated into current treat-
ment regimens represents an appealing possibility to
increase efficacy of anti-leukemic therapy. Examples for
such a strategy are modulation of survival and cell death
pathways through small molecules, such as the BCL-2
mimetic venetoclax7,8, inhibitors of the PI3K/AKT/
mTOR pathway such as Torin, or of the MEK pathway
such as Trametinib9,10. Another strategy exploits the
potential of small molecules to activate non-apoptotic cell
death pathways, such as the IAP inhibitor birinapant,
which we showed to activate necroptosis to potently
interfere with leukemia progression11,12. Common to all
these strategies is the need for the development of func-
tional approaches to identify the target patient population
which is most likely to respond. Compounds that are
clinically used for non-cancer indications may represent
an appealing source for a novel treatment approach.
© The Author(s) 2020
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Beat C. Bornhauser (beat.bornhauser@kispi.uzh.ch)
1Department of Oncology and Children’s Research Center, Children’s Hospital
Zurich, Lengghalde 5, Balgrist Campus AG, 8008 Zurich, Switzerland
2Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin
Berlin, Campus Virchow Klinikum, Berlin, Germany




















































Repurposing potential anti-leukemic drugs for ALL
treatment may accelerate clinical development, and will
reduce cost and time required for the introduction in the
clinic13,14. We performed a functional imaging-based drug
repurposing screen using an extended FDA-approved
drug library, which we tested on primary relapsed ALL
co-cultured on mesenchymal stroma cells (MSCs) in a
model of the bone marrow microenvironment15. Unex-
pectedly, we identified the anthelmintic agents mox-
idectin, ivermectin, and milbemycin to have a high
anti-leukemic potential as single agents and to exhibit
synergistic activity with the BCL-2 inhibitor navitoclax
(ABT-263) and standard chemotherapeutic agents of
frontline ALL therapy, such as dexamethasone in highly
refractory primary ALL.
Materials and methods
Human and patient-derived xenograft (PDX) samples
Primary human ALL samples were obtained from
cryopreserved bone marrow aspirates of patients enrolled
in the AIEOP-BFM 2009 and ALL-REZ 2002 studies.
Informed consent was obtained in accordance with the
Declaration of Helsinki, and approval was granted by the
Ethics Commission of the Kanton Zürich (approval no.
2014–0383). Samples were classified as standard risk (SR),
medium risk (MR), high risk (HR), very high risk (VHR),
and relapse (R) samples according to the clinical criteria
used in the ALL-BFM 2000 study16. Primary human ALL
cells were transplanted into 5- to 12-week-old immuno-
deficient NOD/SCID/IL2rγnull (NSG) mice in order to
obtain PDX cells17. Leukemia progression was monitored
weekly by staining peripheral blood after red blood cell
lysis with hCD19-PE and hCD45-Alexa Fluor 647 (Bio-
legend) and analyzed by flow cytometry (Fortessa LSR, BD
Biosciences). Engrafted ALL cells were collected from the
spleen. In vivo experiments were approved by the veter-
inary office of the Canton of Zurich.
Ex vivo drug screen
The drug screen was performed with ALL cells grown in
co-culture on MSCs in 384-well plates15. Briefly, 2500
MSCs in 30 µL AIM-V (Thermo Fisher Scientific) med-
ium per well were plated 24 h before adding 25,000 ALL
cells in 27.5 µL of AIM-V using a Biotek EL406 microplate
washer/dispenser. The drug library of 2487 FDA-
approved (Nexus platform ETH) compounds at 1 µM
drug concentration was applied 24 h after the seeding of
ALL cells with a Tecan EVA 100 liquid handling robot
(Nexus platform ETH). Treated cells were incubated at
37 °C with 5% CO2 and 95% humidity for 72 h. Cell via-
bility was evaluated by CyQuant staining (Thermo Fisher
Scientific) and analyzed by TTP Labtech Acumen Cellista.
Specific details on antibodies and other reagents are given
in Supplementary Table S1.
Statistical analysis of ex vivo drug screen
Systematic variation from plate to plate was removed by
standard normalization procedures18. Following common
practice, assay quality was evaluated on the basis of the Z′
factor. To eliminate within-plate edge effects a smooth
polynomial correction was applied using the Loess func-
tion19. Differential activity was analyzed following the
workflow sketched in ref. 20. Briefly, for each single-dose
measurement of a compound, a Z-test was performed
against the Null hypothesis that its activity is indis-
tinguishable from the negative controls. For this to be
valid, the distribution of activities of the negative controls
was checked to be normal. The mean and variance of the
distribution was estimated robustly for each plate and
smoothly averaged over a range of consecutive plates. The
drug activity was ranked based on the percentage of the
positive control idarubicin.
Ex vivo dose response and synergy profiling
Drug sensitivity and drug synergy profiles were eval-
uated using ALL cells in co-culture with MSCs as
described above. A Tecan D300 robot was used to dis-
pense drugs at the indicated dilutions. ABT-263 (navito-
clax) and dexamethasone (Selleckchem) concentrations
for synergy were based on the half maximal inhibitory
concentration (IC50) of the different samples screened.
Cell viability was evaluated after 72 h of drug treatments
using CyQuant staining and imaging-based cell viability
analysis on an ImageXpress microscope (Molecular
Devices; ref. 15). All the dose response curves and the IC50
were represented and calculated using GraphPad Prism 8.
The synergy was calculated using SynergyFinder tool21,22.
The resulting ZIP score indicates synergism (ZIP score ≥
1), additivity (ZIP score 0–1) or antagonism (ZIP score ≤
0), and is here represented by a 3D graph21,22.
Generation of knockout PDX cells
Knockout PDXs of RIPK1 (RIPK1KO) and of Caspases-
3 and -7 (C3/C7KO) were generated using the multicolor
lentiCRISPR system11,23. The triple knockout containing
depletion of Caspase-2 (C3/C7/C2KO) or Caspase-6 (C3/
C7/C6KO) was produced transducing C3/C7KO cells
with the lentiviral vector sg_shuttle_RFP657 (ref. 24)
containing the respective sgRNAs. Transduced cells were
transplanted into NSG mice for expansion, subsequently
sorted and retransplanted to obtain a pure knockout
population. The knockout was confirmed by western
blotting. The sgRNAs used for RIPK1, Caspase-3, Cas-
pase-7, Caspase-6, and Caspase-2 were published in
refs. 11,23,25.
Intracellular chloride measurement
Intracellular chloride concentration was assessed using
the fluorescent indicator MQAE (Thermo Fisher
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Scientific). In total, 500,000 ALL cells were recovered in
300 µL AIM-V conditioned medium, which was harvested
upon 24 h incubation of MSC monocultures. After 1 h of
recovery, the ALL cells were treated with moxidectin
(Sigma Aldrich) (1, 2, and 3 µM) or ivermectin (Sell-
eckchem) (1 or 3 µM) for 2 or 4 h. The cells were then
incubated at 37 °C for 1 h with MQAE (1 mM) and for
15min with PI (Thermo Fisher Scientific). After staining,
the cells were collected, centrifuged, and resuspended in
fresh 1× phosphate-buffered saline (PBS). MQAE fluor-
escence was quantified in PI-negative cells by flow cyto-
metry (Fortessa LSR, BD Biosciences). Results were
analyzed by FlowJo 10.2 and statistical analysis was per-
formed using GraphPad Prism 8 with t-test analysis.
Measurement of mitochondrial outer membrane
permeabilization (MOMP)
Evaluation of MOMP was done using the fluorescent
dye tetramethylrhodamine ethyl-ester (TMRE) (Thermo
Fisher Scientific). In total, 500,000 cryopreserved ALL
cells were recovered for 1 h in 300 µL AIM-V medium.
Upon recovery, ALL cells were treated with moxidectin
(1, 2, or 3 µM) or ABT-263 (50, 100, or 250 nM) for 2 h
and subsequently incubated at 37 °C for 15min with
TMRE (50 nM). After staining, the cells were collected,
centrifuged, and resuspended in 1× PBS. TMRE fluores-
cence was quantified by flow cytometry (Fortessa LSR, BD
Biosciences). Results were analyzed by FlowJo 10.2 and
statistical analysis was performed using GraphPad Prism 8
with t-test analysis.
Results
Ex vivo drug screen identifies antiparasitic compounds as
promising candidates to target refractory leukemia
To identify novel compounds with anti-leukemia
potential, we used a co-culture model of primary ALL
cells on MSCs enabling long-term survival ex vivo
(Fig. 1a)15. On this platform, we tested 2487 FDA-
approved compounds (Supplementary Table S2) at 1 µM
by using a fluorescent cell viability readout combined with
automated imaging analysis. After normalization of cell
viability to the effect of the highly potent anthracycline
idarubicin, we identified 61 compounds with strong anti-
leukemia activity (Fig. 1b, Supplementary Fig. S1A, B). As
expected, the majority of these drugs were chemother-
apeutic agents that are already in clinical use to treat
leukemia. Among these, we found DNA-intercalating
agents, including mitoxanthrone, daunorubicine, or dox-
orubicine, which appeared to have the strongest anti-
leukemia effect among the screened compounds (Fig. 1c,
Supplementary Fig. S1A). Furthermore, agents with
known anti-leukemia activity, e.g. steroids, proteasome,
and HDAC inhibitors, but also BCL-2 and cIAP antago-
nists or tyrosine kinase inhibitors also emerged with
potent anti-leukemia activity (Supplementary Fig. S1A, B).
Unexpectedly, we further identified several agents from
drug families that have, so far, not been associated with
anti-leukemia activity. For instance, anti-fungal and anti-
bacterial agents as well as cardiac glycosides showed
substantial anti-leukemia activity (Supplementary Fig.
S1A, B). The most potent among these were the anthel-
mintic drugs ivermectin, moxidectin, and milbemycin,
which showed up to 80% maximal cytotoxic effect com-
pared to idarubicin (Fig. 1c).
Anthelmintic agents are widely active in precursor B- and
T-ALL
Having identified ivermectin, moxidectin, and milbemy-
cin as potential candidates with anti-leukemia activity, we
first validated the activity of these three drugs by generating
dose response curves on the same ALL sample used for the
screen. Interestingly, all three drugs showed a strong
cytotoxic effect at low micromolar range concentration
with IC50 values between 1.2 and 1.5 µM (Fig. 1d), with
moxidectin showing a slightly higher activity as compared
to ivermectin and milbemycin. To evaluate the potential of
these anthelmintic compounds, we generated dose
response curves for these three agents in 47 precursor B-
ALL and 8 T-ALL PDXs (Fig. 2a). The tested T- and B-
ALL samples responded to the three anthelmintic drugs
with comparable sensitivities among the two leukemia
types, with IC50 values between 300 nM and 2.5 µM for
milbemycin and moxidectin, and a somewhat lower iver-
mectin sensitivity, with some of the tested cases showing
IC50 values higher than 3 µM (Fig. 2a, Supplementary Table
S3). Interestingly, most of the screened samples responded
to moxidectin at IC50 values of 1–1.5 µM, while the
responses to milbemycin were more spread among the
samples (Fig. 2a, Supplementary Table S3). We next
addressed whether we could identify differential sensitiv-
ities in samples from different risk groups, including SR,
MR, HR, and VHR, according to the classification used in
the ALL-BFM 2000 study as well as relapse samples16.
With the exception of one relapsed T-ALL sample that
showed very high sensitivity to ivermectin and milbemycin,
we could not detect relevant differences in the sensitivity to
all three anthelmintic agents across the samples. (Fig. 2b).
It is worth noting though that most of the relapse samples
responded to anthelmintic agents in the same sensitivity
range as compared to the samples collected at diagnosis
(Fig. 2b), suggesting that these agents target a mechanism
that is not being selected during progression from diag-
nosis to relapse.
Anthelmintic drugs induce cell death in absence of effector
caspases and RIPK1
Given the potential of anthelmintic agents to induce
apoptotic cell death26 but also to activate other cell death
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pathways in other cellular systems27,28, we next addressed
which cell death mechanism these drugs trigger in pri-
mary ALL. We tested moxidectin, ivermectin, and mil-
bemycin in PDX samples that were depleted for the
effector caspases-3 and -7 using CRISPR mediated gene
editing (C3/C7KO; Supplementary Fig. 2A, E). Under
apoptosis-incompetent conditions the cells were equally
sensitive to moxidectin, the most potent anthelmintic
agent in ALL (Fig. 2a), with no differences to wild-type
(WT) cells (Fig. 3a, Supplementary Fig. S3A). Further
suggesting a caspase-independent mechanism of cell
death, triple knockout of Caspases-3/-7 and -6 (C3/C7/
C2KO; Supplementary Fig. S2B) or Caspase-2 (C3/C7/
C6KO; Supplementary Fig. S2C) did not rescue the cells
upon moxidectin treatment (Fig. 3b). Given the potential
of primary ALL cells to mount a necroptosis response
upon depletion of SMAC mimetics using birinapant11, we
also tested anthelmintic agents in ALL deficient for RIPK1
(RIPK1KO, Supplementary Fig. S2D), the key mediator of
necroptosis. In several different primary RIPK1KO ALL
samples, we could not detect any difference in the sensi-
tivity to anthelmintic agents compared to WT cells (Fig.
3c, Supplementary Fig. S3B). Even upon simultaneous
inactivation of both cell death pathways, either genetically
upon knockout of caspases-3 and -7 and RIPK1 (C3/C7+
RIPK1KO), or upon pharmacological inhibitors, we could
not detect any difference in the sensitivity (Fig. 3d, Sup-
plementary Fig. S3C). We could also excluded the possi-
bility that moxidectin was triggering autophagy
(Supplementary Fig. S3D). Thus, anthelmintic agents
eradicate ALL through an alternative, caspase-indepen-
dent, non-necroptotic cell death mechanism.
Moxidectin increases the intracellular chloride
concentration and induces depolarization of the
mitochondrial membrane in ALL cells
In nematodes, anthelmintic agents induce chloride influx
by selectively binding GABA-A and glutamate-gated
chloride channels increasing intracellular chloride con-
centrations29–31. In mammalian cells, which are lacking
such glutamate-gated chloride channels, anthelmxintic
agents may bind and modulate other ionotropic, ligand-
gated transmembrane receptors including γ-aminobu-
tyric acid type A (GABAA) receptors
32, glycine recep-
tors33, neuronal α7-nicotinic receptors
34, and purinergic
P2X(4) receptors35. Based on these data, we investigated
the potential of anthelmintic agents to increase intra-
cellular chloride in primary ALL. Indeed, moxidectin
induced a rapid decrease of MQAE fluorescence indica-
tive of increased intracellular chloride (Fig. 4a), already at
2 h of treatment. At 4 h of moxidectin treatment, this
increase in intracellular chloride was even more dramatic
(Fig. 4b, Supplementary Fig. S4A). Likewise, ivermectin
treatment also increased intracellular chloride, albeit to a
smaller extent than moxidectin. Further downstream, an
increase in intracellular chloride may influence the
mitochondria integrity as a gatekeeper for cell death and
survival36. Notably, MOMP is considered a point of no
return in cell death and is able to kill cells even in
absence of caspase activity in a phenomenon known as
MOMP-induced caspase-independent cell death37. Thus,
we used TMRE to assess whether our anthelmintic
agents destabilized the mitochondrial outer membrane
potential. Indeed, moxidectin decreased the mitochon-
drial outer membrane potential of primary leukemia
cells, indicating a strong destabilization of the mito-
chondria (Fig. 4c). Interestingly, the mitochondrial
depolarization upon moxidectin treatment was even
higher than upon treatment with the BCL-2-antagonist
ABT-263, a potent inducer of MOMP38 (Fig. 4d, Sup-
plementary Fig. S4B). Thus, our data suggest that mox-
idectin induces a strong mitochondrial permeabilization
in primary leukemia cells that leads them to a caspase-
independent cell death.
Moxidectin synergizes with ABT-263 and dexamethasone
Given the diverging molecular mechanism of MOMP
induction by ABT-263 and moxidectin, we evaluated the
effects of the combination of moxidectin with ABT-263
using increasing concentrations of both agents simulta-
neously. In all the PDXs tested, sublethal concentrations
of moxidectin enhanced the effect of ABT-263, resulting
(see figure on previous page)
Fig. 1 Ex vivo drug repurposing screen identifies anthelmintic agents as a new option for anti-leukemia therapy. a Strategy for ex vivo drug
screening of patient-derived xenograft (PDX) cells in co-culture with mesenchymal stroma cells (MSCs), which were treated with 2487 compounds
(each at 1 µM concentration) with FDA approval. Fluorescent live cell staining using CyQuant and automated image analysis was used to quantify
living ALL15. b Volcano plot of the resulting drug activity. The horizontal line corresponds to FDR= 0.01 and compounds below this line are labeled
“not significant”. The two vertical lines correspond to a change of ±0.3 in activity as compared to vehicle control and compounds outside this range
are labeled “strong”. The legend refers to “not” (black)—not significant and weak effect; “signif & strong” (light brown)—significant and strong effect;
“signif” (light blue)—significant but weak effect; “strong” (green)—not significant but strong effect. c Rank order of anti-leukemia activity of the 2487
FDA-approved compounds in percentage of the positive control idarubicin. On the left the top drugs with the highest anti-leukemia activity
doxorubicin, mitoxantrone, and daunorubicin are indicated in black. In red, the anthelmintic agents, ivermectin, moxidectin, and milbemycin are
indicated. Funduscein, a drug with high fluorescent characteristics, leads to seemingly proliferative activity revealing a false negative example.
d Validation of anthelmintic compounds, moxidectin, ivermectin, and milbemycin. Dose–response curves of the three drugs for B-R-03 are given
normalized to vehicle treated control. N= 3 independent experiments. All quantifications represent mean ± s.e.m.
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in synergistic drug activity with ZIP score values of 6.4,
5.6, and 9.7 (Fig. 5a, b, Supplementary Fig. S5A).
Further following the hypothesis that activation of cell
death through different mechanisms may enhance killing
in primary ALL, we investigated whether moxidectin
may also sensitize to dexamethasone, a key component
of standard induction chemotherapy in ALL39. Indeed,
sublethal moxidectin increased dexamethasone-
mediated leukemia cell death (Fig. 5c), and we
observed a striking synergistic effect of moxidectin and
dexamethasone in primary ALL samples, with a ZIP
score ≥ 2.4 for 16 out of 19 primary ALL cases tested (Fig.
5d, Supplementary Fig. S5B, Supplementary Table S4).
Thus, anthelmintic agents do not only possess attractive
anti-leukemic potential as single agents, but also syner-
gize with apoptosis inducers and standard chemotherapy
to eradicate resistant leukemia cells.
Discussion
Different approaches may be applied to identify new
treatment strategies for resistant disease. While direct
targeting of oncogenic lesions represents an appealing
approach, its clinical translation has remained challenging
frequently leading to only transient responses. By
Fig. 2 Primary B- and T-ALL samples are sensitive towards anthelmintic compounds. a Violin plot indicating the response of B-ALL (n= 47) and
T-ALL (n= 8) samples to moxidectin, ivermectin, and milbemycin, as indicated by IC50 values. On the ordinate, the three drugs are indicated with the
respective IC50 (Log nM) distribution. Blue squares represent precursor B-ALL and red triangles represent T-ALL samples. b Distribution of IC50 values
in primary ALL with respect to their risk classification. IC50 values are given in Log (nM) of moxidetin, ivermectin, and milbemycin, and classification of
primary ALL samples in standard risk (B-SR; n= 5), medium risk (B-MR; n= 4), high risk (B-HR; n= 3), very high risk (B-VHR; n= 5), and relapse
(B-Relapse; n= 30). Classification of T-ALL samples in non-high risk (T-non-HR; n= 2), very high risk (T-VHR; n= 1), and relapse (T-Relapse; n= 5).
Classification of samples at diagnosis in accordance to the criteria used in the ALL-BFM study16.
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contrast, targeting specific pathways, on which leukemia
cells rely, has been more promising for drug development,
exemplified by venetoclax targeting BCL-2 or PI3K/AKT/
mTOR inhibitors7,8,10. We here report on a drug repur-
posing screen that we conducted in refractory primary
human ALL cells, using an extended FDA-approved drug
library. We identified the anthelmintic agents, ivermectin,
moxidectin, and milbemycin, as novel agents with high
anti-leukemic potential for refractory ALL. These com-
pounds had a strong anti-leukemic effect ex vivo in pri-
mary leukemia cells at low micromolar concentrations,
extending earlier studies that described activity of iver-
mectin in acute myeloid leukemia (AML) and other pri-
marily solid tumors26,28,40,41. Next to anthelmintic agents,
we also identified other compound families with potential
anti-leukemic agents, such as bactericidal and fungicidal
agents. However, these compounds were active in con-
centrations that could never be reached in vivo, while the
vast experience with anthelmintic agents indicates that
these could be applied at active anti-leukemic con-
centrations in vivo (NCT03012828 (ref. 42)). The anthel-
mintic agent ivermectin has been widely used to eliminate
ectoparasites43, while moxidectin has been recently
approved by the FDA to treat onchocerciasis in humans44.
Among the anthelmintic agents, moxidectin has earlier
been shown to have a safer profile and a better efficiency
when applied as antiparasitic treatment compared to
ivermectin44,45. Furthermore, several clinical trials invol-
ving moxidectin did not report severe adverse effects at
doses four time higher than the one used to treat human
onchocerciasis (NCT03012828 (ref. 46)). Moreover, the
chemical structure of moxidectin with high lipophilicity
increases the half-life of the drug47, an observation that
may be linked to its higher drug efficiency, as compared to
other anthelmintic agents. Ivermectin on the other hand
has been safely used in immunocompromised patients to

































































































































































































Fig. 3 Anthelmintic agents induce cell death independent of caspases and RIPK1. Dose response curves of B-R-03 wild type (WT) and indicated
gene knockout (KO) ALL are given. a Moxidectin (Mox; black), ivermectin (Ive; orange), and milbemycin (Mil; green) induce cell death in WT
(continuous lines) and Caspases-3 and -7 KO (C3/C7KO; dotted lines) ALL. b Moxidectin induces cell death in WT (black), C3/C7KO (gray), Caspases-3/-
7/-2 triple knockout (C3/C7/C2KO; green), and Caspases-3/-7/-6 triple knockout (C3/C7/C6KO; orange) ALL. c Moxidectin (black), ivermectin (orange),
and milbemycin (green) induce cell death in WT (continuous lines) and RIPK1KO (dotted lines) ALL. d Moxidectin induces cell death in WT (black), C3/
C7KO (gray), RIPK1KO (orange), and combination of C3/C7 and RIPK1 knockout (C3/C7+RIPK1KO; green). All the dose response curves were
normalized to vehicle control, and performed in N= 3 independent experiments. Quantifications represent mean ± s.e.m.
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treat scabies48,49. This attractive safety profile, together
with the sensitizing activity towards steroids, warrants
further clinical development of anthelmintics, possibly
not as single agents but in combination with standard
chemotherapy to eradicate minimal residual disease and
to prevent relapse. Yet another aspect supporting clinical
development arises from activity of anthelmintics across
samples from different risk groups including SR ALL. The
potential of these agents to improve the response to
steroids also in good responding cases and potentially to
decrease toxicity could be tested in a clinical trial.
In nematodes, anthelmintic agents target glutamate-
gated chloride channels to increase intracellular chloride
concentrations, which is lethal to the parasites47. Since
these chloride channels are lacking in humans, anthel-
mintics must have alternative targets to activate cell
death. While GABA-gated chloride channels have been
shown to act as potential mediators to increase intracel-
lular chloride upon ivermectin50, targeting the Ca2+-
activated chloride channel TMEM16A by anthelmintics
was recently shown to confer susceptibility to these
agents51. TMEM16A is indeed widely expressed in human
cancers52, but also in human leukemia (https://pecan.
stjude.cloud/home), and an increase in intracellular
chloride upon expression of synthetic chloride transpor-
ters has been reported to induce mitochondrial alterations
and cell death36,53. Further supporting a role for
TMEM16A in tumor biology, its expression also increased
BCL-2 with subsequent breast tumor progression54, and
its downregulation induced apoptosis55. Future functional
experiments including for instance CRISPR-based loss of
function studies will shed light on the mechanistic
requirement of chloride channels for moxidectin action,
taking into consideration that several different mechan-
isms may contribute to chloride homeostasis in ALL.
Irrespective of the underlying control mechanism, intra-
cellular chloride is increased upon treatment with





























































































Fig. 4 Moxidectin induces leukemia cell death by increasing intracellular chloride and inducing mitochondrial outer membrane
permeabilization (MOMP). a Levels of intracellular chloride in B-R-03 PDX cells as measured by quenching of the MQAE fluorescent signal upon
treatment with 3 µM moxidectin (Mox, blue), compared to vehicle control (black). Representation of one experiment after 4 h treatment.
b Quantification of intracellular chloride in vehicle treated B-R-03 (black) compared to cells treated with moxidectin (Mox) 1 µM (light blue), 2 µM
(blue), and 3 µM (dark blue) or ivermectin (Ive) 1 µM (light green) and 3 µM (green) for 2 or 4 h. Quantifications of N= 6 independent experiments
representing mean ± s.e.m., Paired t-test, *p value ≤ 0.008; **p value ≤ 0.002. c MOMP levels in B-R-03 PDX cells. Light color histograms represent cells
treated with 2 µM Moxidectin (Mox; blue) or 100 nM ABT-263 (ABT; orange) compared to control cells (black). Representation of one experiment after
2 h treatment. d MOMP quantification in control B-R-03 (black) ALL cells compared to cells treated with moxidectin (Mox) 1 µM (light blue), 2 µM
(blue), and 3 µM (dark blue) or ABT-263 (ABT) 50 nM (light pink), 100 nM (orange), and 250 nM (brown) for 2 h. Quantifications of N= 3 independent
experiments representing mean ± s.e.m. Paired t-test, *p value ≤ 0.02; **p value ≤ 0.01.
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Fig. 5 Synergic activity of moxidectin and ABT-263 or dexamethasone. a On the left, the viability curve of the B-R-03 sample treated with ABT-263 (ABT;
black) or ABT-263 in combination with 0.9 µMmoxidectin (ABT+Mox; gray). The dose response curve was performed in N= 3 independent experiments, and
quantifications represent mean ± s.e.m. On the right, a 3D representation map of the B-R-03 sample with the calculated synergy (Z-score= 9.789) between
moxidectin and ABT-263. b Heatmap representing the synergy between moxidectin and ABT-263 of B-ALL samples (n= 3). The samples (columns) were
ordered, from the left to the right, according to their decreasing Z-score values. c On the left, the viability curve of the B-VHR-12 sample treated with
dexamethasone (Dex; black) or dexamethasone in combination with 0.5 µM moxidectin (Dex+Mox; gray). The dose response curve was performed in N= 3
independent experiments, and quantifications represent mean ± s.e.m. On the right, a 3D representation map of the B-VHR-12 sample with the calculated
synergy (Z-score= 20.233) between moxidectin and dexamethasone. d Heatmap representing the synergy between moxidectin and dexamethasone of B-
ALL (n= 14) and T-ALL (n= 5) samples. The samples (columns) were ordered, from the left to the right, according to their decreasing Z-score values.
Mezzatesta et al. Blood Cancer Journal           (2020) 10:72 Page 9 of 11
Blood Cancer Journal
mitochondrial outer membrane and cell death, corro-
borating the results of a previous study in AML40. The
balance of intracellular chloride is required for cellular
homeostasis56, and alteration of its intracellular con-
centrations can destabilize mitochondria and trigger cell
death. Susceptibility to increased intracellular chloride
thus appears to represent a distinct vulnerability in leu-
kemia cells, which does neither depend on presence of the
apoptosis executioner caspases-3 and -7 nor on activation
of the alternate necroptosis cell death mechanism. Rather,
osmotic stress may underlie the potent anti-leukemia
activity of anthelmintic agents. Underscoring the impor-
tance of mitochondrial integrity for survival and cell death
in leukemia, synergistic effect of increasing intracellular
chloride using moxidectin and antagonizing BCL-2 using
navitoclax enhanced the cell death mechanism. Such dual
induction of mitochondrial damage may also underlie the
synergistic activity of moxidectin with dexamethasone,
which has been shown to upregulate BCL-2 family
members to reactivate apoptosis57. Thus, we envisage that
single agent activity of anthelmintics will not be a solution
to treat resistant disease. Rather, combination with stan-
dard chemotherapy should be tested in a clinical trial in
order to assess their anti-leukemic potential.
Taken together, our data show that repurposing screens
do identify novel agents with anti-cancer activity. While
such phenotypic screens, as opposed to CRISPR-based
genomic screens, may not identify molecular mechanisms
that confer sensitivity or resistance to given approaches,
they do provide the basis for the identification of new
agents with so far unappreciated anti-cancer activity.
Based on the knowledge obtained on the agents so far, it
will be possible to develop and validate biomarkers to
identify vulnerabilities and potential responses. The ability
of anthelmintics to induce cell death independent on
apoptosis and necroptosis underscores their potential as
novel anti-leukemic agents, supporting the notion that
simultaneous activation of several different cell death
pathways represents a powerful approach to develop
novel treatment strategies for refractory disease.
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